Actelion does not see significant CVS hit to Opsumit sales

August 3, 2016 10:51 AM

31 0

Actelion does not see significant CVS hit to Opsumit sales

ZURICH Big U.S. pharmacy chain CVS Health's move to jettison an Actelion drug from a list of covered medications is not expected to have a "meaningful impact" on the Swiss biotechnology company's sales, a spokesman said on Wednesday.

CVS on Tuesday released a list of more than 30 drugs it was removing from its 2017 standard formulary, including Actelion's Opsumit for deadly pulmonary arterial hypertension, or PAH.

Also read: McKesson to Pay $150 Million for Failing to Report ‘Suspicious’ Drug Orders

Read more

To category page

Loading...